search
Back to results

The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases

Primary Purpose

Cancer, Inflammation

Status
Completed
Phase
Locations
United States
Study Type
Observational
Intervention
Sponsored by
Jonsson Comprehensive Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an observational trial for Cancer focused on measuring 18F-FAC, imaging, cancer, inflammation, PET

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • > 18 years of age
  • women of childbearing potential will undergo a pregnancy test free of charge
  • patients with cancer or autoimmune diseases or healthy subjects

Sites / Locations

  • UCLA

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Arm Label

patients with cancer

patients with autoimmune diseases

healthy subjects

Arm Description

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
August 11, 2010
Last Updated
July 27, 2012
Sponsor
Jonsson Comprehensive Cancer Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01180907
Brief Title
The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases
Official Title
The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases: A Pilot Study
Study Type
Observational

2. Study Status

Record Verification Date
July 2012
Overall Recruitment Status
Completed
Study Start Date
November 2007 (undefined)
Primary Completion Date
November 2011 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jonsson Comprehensive Cancer Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to determine whether positron emission tomography using the new imaging agent 18F-FAC can be used for imaging cancer and/or inflammation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer, Inflammation
Keywords
18F-FAC, imaging, cancer, inflammation, PET

7. Study Design

Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
patients with cancer
Arm Title
patients with autoimmune diseases
Arm Title
healthy subjects

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: > 18 years of age women of childbearing potential will undergo a pregnancy test free of charge patients with cancer or autoimmune diseases or healthy subjects
Study Population Description
patients with cancer, autoimmune diseases and healthy subjects
Sampling Method
Non-Probability Sample
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christiaan Schiepers, M.D. Ph.D
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCLA
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States

12. IPD Sharing Statement

Learn more about this trial

The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases

We'll reach out to this number within 24 hrs